Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.

Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L.

Fertil Steril. 2003 Nov;80(5):1234-40.

PMID:
14607581
2.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT..

Maturitas. 2005 Sep 16;52(1):1-10. Review.

PMID:
15963666
3.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669
4.

Hormone replacement therapy in postmenopausal women.

Yasui T, Uemura H, Takikawa M, Irahara M.

J Med Invest. 2003 Aug;50(3-4):136-45. Review.

PMID:
13678382
5.

Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.

Gibbons WE, Thorneycroft IH.

J Reprod Med. 1999 Feb;44(2 Suppl):203-8. Review.

PMID:
11392033
6.

Hormone replacement therapy: optimising the dose and route of administration.

Montgomery Rice V.

Drugs Aging. 2002;19(11):807-18. Review.

PMID:
12428992
7.

Low-dose estrogen therapy for menopausal women: a review of efficacy and safety.

Crandall C.

J Womens Health (Larchmt). 2003 Oct;12(8):723-47. Review.

PMID:
14588124
8.

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.

Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000402. doi: 10.1002/14651858.CD000402.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;8:CD000402.

PMID:
19370558
9.

Estrogen, progestogens and cardiovascular risk.

Stefanick ML.

J Reprod Med. 1999 Feb;44(2 Suppl):221-6. Review.

PMID:
11392036
10.

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.

Furness S, Roberts H, Marjoribanks J, Lethaby A.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD000402. doi: 10.1002/14651858.CD000402.pub4. Review.

PMID:
22895916
11.

Optimizing the dose of hormone replacement therapy.

Rice VM.

Int J Fertil Womens Med. 2002 Sep-Oct;47(5):205-10. Review.

PMID:
12469707
13.

Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.

Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C.

Menopause. 2001 Nov-Dec;8(6):420-3. Review.

PMID:
11723414
14.

Low-dose hormone replacement therapy: effects on bone.

Gambacciani M, Monteleone P, Genazzani AR.

Climacteric. 2002 Jun;5(2):135-9. Review.

PMID:
12051108
15.

Impact of WHI conclusions and ACOG guidelines on clinical practice.

Gass M.

Int J Fertil Womens Med. 2003 May-Jun;48(3):106-10; discussion 137-8. Review.

PMID:
12839140
16.

Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.

Maki PM, Henderson VW.

Climacteric. 2012 Jun;15(3):256-62. doi: 10.3109/13697137.2012.660613. Review.

17.

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

Taylor HS, Ohleth K.

Menopause. 2012 Apr;19(4):479-85. doi: 10.1097/gme.0b013e31823dbbca. Review.

PMID:
22278343
18.

A critique of the Women's Health Initiative hormone therapy study.

Klaiber EL, Vogel W, Rako S.

Fertil Steril. 2005 Dec;84(6):1589-601. Review.

PMID:
16359951
19.

Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe?

Stanczyk FZ, Bhavnani BR.

J Steroid Biochem Mol Biol. 2014 Jul;142:30-8. doi: 10.1016/j.jsbmb.2013.11.011. Epub 2013 Nov 26. Review.

PMID:
24291402
20.

Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data.

Mirkin S, Komm BS, Pickar JH.

Expert Opin Drug Saf. 2014 Jan;13(1):45-56. doi: 10.1517/14740338.2013.824965. Epub 2013 Aug 7. Review.

PMID:
23919270

Supplemental Content

Support Center